90098-38-7

Basic information

• Product Name: methyl 2-(4-chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propionate
• Synonyms: methyl 2-(4-chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propionate
• CAS NO: 90098-38-7
• Molecular Weight: 384.819
• Mol File: 90098-38-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: methyl 2-(4-chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propionate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(4-chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propionate(90098-38-7)
• EPA Substance Registry System: methyl 2-(4-chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propionate(90098-38-7)

Safety Data

• Hazardous Substances Data: 90098-38-7(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 90098-04-7 rebamipide 
• 74-88-4 methyl iodide 
• 4876-14-6 2-amino-3-<2-(1H)-quinolinon-4-yl>propionic acid hydrochloride 
• 4900-38-3 2-acetylamino-2-(ethoxycarbonyl)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propionic acid ethyl ester 
• 4876-10-2 4-bromomethyl-2(1H)-quinolinone 

Relevant articles and documents

Sodium Salts and Solvate of Rebamipide: Synthesis, Structure, and Pharmacokinetic Study

Two sodium salts (Na(CH3CH2OH) (HReb) (1) and Na2(H2O)4(Reb) (2)), one methanol solvate (H2Reb·CH3OH (3)), and one methyl ester (4) of the minimally soluble drug, rebamipide (H2Reb), used for the treatment of gastric ulcers and gastritis have been synthesized. For the first time the structure of rebamipide has been determined by single crystal X-ray diffraction. Although salts 1 and 2 were prepared under the similar conditions, their structures are different. In 1, rebamipide loses the proton of the carboxyl group to interact with the sodium ion, but in 2 the drug molecule converts to its prototropic tautomer and then simultaneously loses the protons of the carboxyl and hydroxyl groups to form salt. Control experiments show that reaction temperature is the key factor influencing the formation of salts. Although all methanol was used in the synthesis of 3 and 4, in 3 methanol acts as solvent involved in the lattice, while in 4 it reacts with rebamipide to form ester. By analyzing the mass spectra of the reaction solution, we speculate that the crystallization of 3 and 4 is controlled by the products solubility. Dissolution studies indicate that both the maximum solubility and dissolution rate of 1-4 in simulated succus gastricus are improved. Furthermore, pharmacokinetic behavior of compounds 1-4 was investigated in rats and the results indicate that the bioavailability of 1, 3, and 4 upon oral administration is enhanced compared to that of API.

NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF

Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided. The rebamipide prodrug is increased 25-fold in abso

Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-Chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid and related compounds

-